Intelligencia AI’s Post

As #ASH2024 wrapped up this week, we at Intelligencia AI highlighted a select group of biotech companies that stood out in their fields. Our AI-driven PTRS predictions had already identified these programs as top performers within their competitive landscapes, and the results they announced at ASH validated our assessments. Curious to learn more? Dive into how we evaluated these companies, their standout features, and the impressive results they’ve shared here 👇

Learn how Notable Labs is pioneering the integration of artificial intelligence (AI) into predictive precision medicine in this informative California Life Sciences (CLS) article, written by Chris Leonardi, Head of Clinical Alliances and Partnerships.  Chris explores how predictive precision outcomes compare to traditional methods, as was showcased at the 2023 American Association for Cancer Research (AACR) annual meeting. He also describes how AI’s ability to navigate complex datasets without prior knowledge of a drug’s specific cellular biology contributes to a comprehensive understanding of drug efficacy. Read more at https://lnkd.in/eBxUNsBz #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS #AcuteMyeloidLeukemia #artificialintelligence #AI #drugefficacy

2024 Life Science #IPOs! Key drivers include: Later stage assets and #clinical #trial results. Multiple early stage assets with #platform technology TA Focus: #Oncology / #cancer, #Neuro/ #CNS; #Inflammation/ #Immunology TM focus #smallmolecules, #biologics, #genetherapy, and #celltherapy. The median #IPO is $110M with a high of $380M. #funding #publicofferings #biotech #biopharma Kyverna Therapeutics; CG Oncology; Contineum Therapeutics; Boundless Bio; Chromocell Corporation; Metagenomi; Telomir Pharmaceuticals, Inc.; Alto Neuroscience; Fractyl Health; Autonomix Medical; ArriVent Biopharma #ai #datascience #machinelearning #ML #VC #biopharma #biotech #CFO #ipos

🔍Check out OncoVI, our latest work available as a preprint on medRxiv and GitHub! 💉Nowadays, accurate and reproducible classification of somatic variants is essential in precision oncology. 💡We have developed OncoVI (Oncogenicity Variant Interpreter): a fully-automated Python-based implementation of the oncogencity guidelines (Horak et al., Genetics in Medicine, 2022). 🔓OncoVI facilitates the adoption of the oncogenicity guidelines, thus taking a further step towards harmonising the interpretation of somatic variants. 🌈 Many thanks to Dr Fulvia Ferrazzi for her supervision throughout the project! 🍀 Stay tuned for updates! #precisiononcology #precisionmedicine #somaticvariants #variantinterpretation #oncogenicity #automatedimplementation ➡️Preprint: https://lnkd.in/drRtVkgB ➡️GitHub: https://lnkd.in/dRMYQ4qz

Biomarker detection remains a critical need across the drug discovery, drug development, and biotech/biopharma industries. Identifying new biomarkers has the potential to drive breakthrough therapeutics in areas such as hematology, oncology, and immunology. At Stabilux, our cutting-edge Bright Technology is designed to revolutionize these efforts. With applications in emerging fields like imaging, (spatial biology, omics) and full-spectrum cytometry (imaging flow, spectral flow) we enable the detection of rare markers and proteins that can unlock new possibilities in research and treatment. Let's explore collaborative opportunities and see how we can work together to achieve impactful results. #Stabilux #BiotechInnovation #BiomarkerDetection #BrightTechnology 

Stabilux continues to develop the technologies needed to enhance and detect biomarkers as well as antibody complexes with high brightness dyes. 2025 will be a breakthrough year!

Our CEO, {{linkedin_mention(urn:li:person:MG8_4hSnpb|Avi Veidman)}}, was interviewed by {{linkedin_mention(urn:li:person:vgKi_zBgFc|Brian K. Buntz)}} for {{linkedin_mention(urn:li:organization:9334323|Drug Discovery & Development)}}! Avi shares how Nucleai's AI-driven spatial biomarkers aim to accelerate drug development: “We’re helping find the right drug for patients while making clinical trials shorter and more likely to succeed for pharma companies, potentially saving years and billions of dollars in drug development.” Learn how Nucleai is leading the way as the first company with an algorithm in active clinical trials. Read more: https://lnkd.in/gpUFUe2Z #SpatialBiology #AI #Oncology #SpatialBiomarkers #Biomarkers #ClinicalTrials #DigitalPathology #PrecisionMedicine #CDx

Our portfolio company Insilico Medicine has announced a major milestone in its multi-year collaboration with Sanofi. Following their 2022 partnership, Insilico Medicine and Sanofi have identified a promising first-in-class lead compound targeting an undruggable transcription factor, with potential applications in oncology treatment. In this collaboration, they first utilized Insilico Medicine's AI-driven biology platform, PandaOmics, and establish a joint research team focused on pioneering targets traditionally considered “undruggable.” Leveraging the flexibility of the company's generative AI drug design engine, Chemistry42, the team then developed and optimized novel molecular scaffolds. #AIinHealthcare #PharmaAI #GenerativeAI #Oncology #DrugDiscovery #Biotech #QimingPortfolio #QimingHealthcare

I had the pleasure today to be presenting, at the Precision Medicine in Oncology 2024 Summit in Barcelona, « 𝗛𝗼𝘄 𝗖𝗗𝗠𝗢𝘀 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 𝘄𝗶𝘁𝗵 𝗣𝗵𝗮𝗿𝗺𝗮 𝗮𝗻𝗱 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝘁𝗼 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝘁𝗵𝗲𝗶𝗿 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗽𝗿𝗼𝗷𝗲𝗰𝘁𝘀 𝗶𝗻 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 », along with several experts during two days. Several topics were covered, such as how to address patient diversity (in terms of Genomics, but also epigenetics and microbiota, with AI tools allowing to decipher datasets) and tumor heterogeneity. In order to bring personalized medicines to the clinic and the market, relevant biomarkers need to be identified and companion diagnostics have to be developed. Oncology therapies, becoming more diverse in terms of modalities and more complex in terms of chemistry/biology (from potent small molecules to cell therapy), also require an adapted manufacturing environment to be delivered for clinical trials and to the patients. Many thanks to the organizers, and to the attendees for very interesting discussions. #oncology #PrecisionMedicine #Pharmaceuticals #Seqens

𝙀𝙢𝙚𝙧𝙜𝙞𝙣𝙜 𝙏𝙧𝙚𝙣𝙙𝙨 𝙞𝙣 𝙩𝙝𝙚 𝘽𝙧𝙖𝙞𝙣 𝙏𝙪𝙢𝙤𝙧 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙞𝙨 & 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨 𝙈𝙖𝙧𝙠𝙚𝙩 𝙎𝙚𝙘𝙪𝙧𝙚 𝙖 𝙁𝙍𝙀𝙀 𝙎𝙖𝙢𝙥𝙡𝙚: https://lnkd.in/g6QwVu9V The 𝘽𝙧𝙖𝙞𝙣 𝙏𝙪𝙢𝙤𝙧 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙞𝙨 & 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨 𝙈𝙖𝙧𝙠𝙚𝙩 is experiencing dynamic growth, fueled by advancements in medical technology and a deeper understanding of neuro-oncology. As we navigate through 2024, several key trends are shaping the landscape: 𝙄𝙣𝙣𝙤𝙫𝙖𝙩𝙞𝙫𝙚 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙩𝙞𝙘 𝙏𝙤𝙤𝙡𝙨: Cutting-edge imaging technologies, such as advanced MRI and PET scans, are revolutionizing the early detection of brain tumors. These tools enhance accuracy, allowing for timely intervention and improved patient outcomes. 𝙏𝙖𝙧𝙜𝙚𝙩𝙚𝙙 𝙏𝙝𝙚𝙧𝙖𝙥𝙞𝙚𝙨 & 𝙋𝙧𝙚𝙘𝙞𝙨𝙞𝙤𝙣 𝙈𝙚𝙙𝙞𝙘𝙞𝙣𝙚: The shift towards personalized medicine is leading to the development of targeted therapies that address specific genetic mutations and molecular characteristics of brain tumors. This approach is significantly improving treatment efficacy and minimizing side effects. 𝙄𝙢𝙢𝙪𝙣𝙤𝙩𝙝𝙚𝙧𝙖𝙥𝙮 & 𝙉𝙤𝙫𝙚𝙡 𝙏𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩𝙨: Emerging therapies, including immunotherapy and gene editing techniques, are showing promise in treating brain tumors that were previously considered resistant to conventional methods. These innovative treatments offer new hope for patients. 𝙆𝙚𝙮 𝙋𝙡𝙖𝙮𝙚𝙧𝙨: The brain tumor diagnosis & therapeutics industry comprises of various key market players such as Pfizer, Amgen, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Novartis, Karyopharm Therapeutics Inc., Canon Medical Systems Corporation, Lantern Pharma Inc. (Nasdaq: LTRN), and others. 𝘼𝙘𝙘𝙚𝙨𝙨 𝙁𝙪𝙡𝙡 𝙍𝙚𝙥𝙤𝙧𝙩: https://lnkd.in/gGz6zwUT As we move forward, collaboration between researchers, clinicians, and industry leaders will be crucial in advancing treatments and improving patient care. Let’s continue to support innovation and drive progress in this vital field! #braintumor #neurooncology #medicalinnovation #healthcare #precisionmedicine #immunotherapy #markettrends #marketresearch #globalindustry